Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06706622 · ClinicalTrials.gov registry record · Phase 3
A Trial of Amlenetug (Lu AF82422) in Participants With Multiple System Atrophy (MSA)
A Phase 3 study of Multiple System Atrophy, sponsored by H. Lundbeck A/S.
- Active
- Registry status
- Phase 3
- Development phase
- 357
- Enrollment target
- 20
- Study locations
NCT06706622: Active Phase 3 study of Multiple System Atrophy, sponsored by H. Lundbeck A/S.
NCT06706622 is a Phase 3 study of Multiple System Atrophy that is active but no longer recruiting, run by H. Lundbeck A/S. The registered enrollment target is 357 participants, above the 257-participant average among 30 other Multiple System Atrophy trials with a reported enrollment target (39% higher). The trial reports 20 study locations across 16 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06706622, a Phase 3 study of Multiple System Atrophy, is active but no longer recruiting, sponsored by H. Lundbeck A/S.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 357 participants
- Enrollment target
- 20
- Study locations
Study Summary
The main goal of this trial is to evaluate the efficacy and safety of amlenetug for the treatment of participants with Multiple System Atrophy (MSA).
Primary Outcome
Mortality-adjusted clinical progression will be assessed by the composite endpoint modified Unified Multiple System Atrophy Rating Scale (mUMSARS) score and time-to-death (any cause).
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Amlenetug
Study Locations (20)
Florida
- Parkinson's Disease And Movement Disorder Center Of Boca Raton - Boca Raton
- University of Florida Norman Fixel Institute for Neurological Diseases - Gainesville
Massachusetts
- Brigham and Women's Hospital - Boston
- Beth Israel Deaconess Medical Center - Boston
New York
- NYU Medical Center - Dysautonomia center - New York
- Columbia University Medical Center - The Neurological Institute of New York - New York
Pennsylvania
- University of Pennsylvania - Philadelphia
- University Of Pittsburgh - Pittsburgh
Arizona
- Mayo Clinic - Scottsdale
Arkansas
- University of Arkansas for Medical Sciences - Little Rock
California
- University of California, San Francisco Neurosciences Clinical Research Unit - San Francisco
Colorado
- CenExel Rocky Mountain Clinical Research, LLC - Englewood
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 357 participants |
| Start Date | 2024-12-03 |
| Est. Completion | 2029-10-25 |
| Phase | Phase 3 |
What the registry record for NCT06706622 still lists
NCT06706622 is an interventional study that assigns participants to a tested intervention. The registered 357 participants enrollment target is mid-sized for trials with a published cap, above the 257-participant average among 30 other Multiple System Atrophy trials with a reported enrollment target (39% higher).
The record links to 1 condition, with Multiple System Atrophy appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06706622 names 20 study sites across 16 states, led by Florida, Massachusetts, New York.
Frequently Asked Questions
What is clinical trial NCT06706622 about?
NCT06706622 is a clinical study titled "A Trial of Amlenetug (Lu AF82422) in Participants With Multiple System Atrophy (MSA)". The main goal of this trial is to evaluate the efficacy and safety of amlenetug for the treatment of participants with Multiple System Atrophy (MSA).
What is the current status of trial NCT06706622?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 357 participants. The study started on 2024-12-03. Estimated completion is 2029-10-25.
What conditions does trial NCT06706622 study?
This clinical trial studies the following conditions: Multiple System Atrophy.
What interventions are being tested in trial NCT06706622?
The interventions under investigation include: Placebo (DRUG), Amlenetug (DRUG).
Who is sponsoring clinical trial NCT06706622?
This trial is sponsored by H. Lundbeck A/S, which has 72 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06706622 being conducted?
This trial has 20 study locations across Arizona, Arkansas, California, Colorado, Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple System Atrophy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06706622's enrollment target sits among peer trials
357 8th of 30 higher than 23 of 30 other Multiple System Atrophy trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Multiple System Atrophy trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
An Extension Trial to Test if TEV-56286 is Effective in Relieving Multiple System Atrophy
RECRUITING · Phase 2
-
Effect of Midodrine vs Abdominal Compression on Cardiovascular Risk Markers in Autonomic Failure Patients
RECRUITING · Early Phase 1
-
Use of Accelerometer for Quantification of Neurogenic Orthostatic Hypotension Symptoms
RECRUITING · NA
-
PET Imaging Evaluation of [11C]SY08
RECRUITING · Early Phase 1
-
A Phase 2 Study of YA-101 in Patients With Multiple System Atrophy
RECRUITING · Phase 2
-
Gait Analysis in Neurological Disease
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06062888 · 357 participants · Phase 2
FFP In Traumatic BRAin INjury (FIT-BRAIN) Trial
- NCT06109766 · 357 participants · NA
Delivering Evidence-Based Parenting Services to Families in Child Welfare Using Telehealth
- NCT06231342 · 357 participants · NA
Endotracheal Tube (ETT) 180: Stylet-loaded Endotracheal Tube Rotation Before Insertion
- NCT06533826 · 357 participants · Phase 2
TReatment of ADC-Refractory Breast CancEr With Dato-DXd or T-DXd: TRADE DXd
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI